Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Arrakis Therapeutics received early financing of $38.0M on 2017-02-27.
| Series | Round size | Date |
|---|---|---|
| Series A | $38M | 02/2017 |
| Series B | $75M | 04/2019 |
| Investors | Security type |
|---|---|
| Canaan | Series A |
| Celgene Corporation | Series A |
| Osage Partners | Series A |
| Henri Termeer | Series A |
| Advent Life Sciences LLP | Series A |
| Pfizer, Inc. | Series A |
| Celgene Corporation | Series B |
| Henri Termeer | Series B |
| Nextech Invest | Series B |
| Pfizer Venture Investments | Series B |
| Omega Funds | Series B |
| venBio Partners | Series B |
| Alexandria Venture Investments | Series B |
| WuXi AppTec Co Ltd | Series B |
| HBM Healthcare Investments AG | Series B |
| Canaan | Series B |
| Osage Partners | Series B |
| GV | Series B |
| Advent Life Sciences LLP | Series B |
Arrakis Therapeutics's top competitor, Merck, earned an annual revenue of $64.2B.
Arrakis Therapeutics's smallest competitor is Homology Medicines with revenue of $-6.7M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Arcturus Therapeutics | - | $152.3M | 150 | - |
| Rgenix | - | $1.3M | 20 | - |
| Synlogic | - | $8,000 | 74 | - |
| Homology Medicines | - | ($6.7M) | 124 | - |
| Skyhawk Therapeutics | - | $580,000 | 30 | - |
| Ribometrix | - | $2.0M | 44 | - |
| Expansion Therapeutics | - | $590,000 | 35 | - |
| Encoded Therapeutics | - | $5.0M | 128 | - |
| Merck | - | $64.2B | 74,000 | - |
| Apexigen | - | $4.9M | 39 | - |
Zippia gives an in-depth look into the details of Arrakis Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Arrakis Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Arrakis Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Arrakis Therapeutics. The data presented on this page does not represent the view of Arrakis Therapeutics and its employees or that of Zippia.
Arrakis Therapeutics may also be known as or be related to Arrakis Therapeutics and Arrakis Therapeutics, Inc.